🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent or Metastatic Solid Tumors

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies NCT05803018Phase 1, Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1 A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Study of ACR-2316 in Specific Advanced Solid Tumors NCT06667141Phase 1, Phase 215 sites📍 Phoenix📍 Beverly Hills📍 Newport Beach Acrivon Therapeutics · Tests: ACR-2316 A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors NCT04794972Phase 16 sites📍 Beijing📍 Chongqing📍 Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. · Tests: GNC-039 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. NCT07483658NA4 sites📍 Gatineau📍 Montreal📍 Montreal CHU de Quebec-Universite Laval · Tests: Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions), Hypofractionated Post-Operative Salvage Radi… Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors NCT06320405Phase 1, Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors NCT07022002Phase 21 site📍 Hangzhou Shenyang Sunshine Pharmaceutical Co., LTD. · Tests: SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites📍 Duarte📍 La Jolla📍 Los Angeles Eli Lilly and Company · Tests: LY4052031, Pembrolizumab Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment NCT02029001Phase 27 sites📍 Bordeaux📍 Lyon📍 Lyon Centre Leon Berard · Tests: Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD) A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors NCT05135975Phase 26 sites📍 Birmingham📍 Aurora📍 Washington D.C. Nationwide Children's Hospital · Tests: Cabozantinib A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. NCT07392736Phase 1, Phase 215 sites📍 Beijing📍 Beijing📍 Hunan Advenchen Laboratories, LLC · Tests: AL8326 tablets, Toripalimab Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors NCT07081984Phase 11 site📍 Shanghai Therorna · Tests: therapeutic tumor vaccine A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors NCT04064359Phase 127 sites📍 Phoenix📍 Los Angeles📍 Santa Monica Oxford BioTherapeutics Ltd · Tests: OBT076, a CD205-directed antibody-drug conjugate Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors NCT05270213Phase 114 sites📍 Scottsdale📍 Tucson📍 Palo Alto Riboscience, LLC. · Tests: RBS2418, Pembrolizumab, Other approved anti-cancer therapy A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours NCT04823897Phase 11 site📍 Edmonton PharmaMatrix Holdings Ltd · Tests: CCI-001 Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites📍 Orlando📍 Boston📍 Oklahoma City Sutro Biopharma, Inc. · Tests: STRO-006, Pembrolizumab Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors NCT06408688Phase 44 sites📍 Baden📍 Basel📍 Liestal University Hospital, Basel, Switzerland · Tests: Immune checkpoint inhibitors plus Iscador® Qu., Immune Checkpoint Inhibitors Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors NCT04119024Phase 13 sites📍 Duarte📍 Los Angeles📍 Stanford Anusha Kalbasi · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA NCT05461664n/a1 site📍 Guangzhou Xinhua Zhang, MD First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer NCT06799065Phase 1, Phase 211 sites📍 Aurora📍 Sarasota📍 Detroit Accent Therapeutics · Tests: ATX-295, ATX-295 and bevacizumab (or biosimilar) Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377Phase 2484 sites📍 Birmingham📍 Mobile📍 Anchorage National Cancer Institute (NCI) · Tests: Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide, anti-PD-1 antibody, Anti-CTLA4 Monoclonal Antibody A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors NCT07015697Phase 131 sites📍 Newport Beach📍 Atlanta📍 Las Vegas Daiichi Sankyo · Tests: Trastuzumab Deruxtecan A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression NCT06051695Phase 1, Phase 212 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B694, A2B543, xT CDx with HLA-LOH Assay A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors NCT06880549Phase 14 sites📍 Los Angeles📍 Grand Rapids📍 San Antonio ModernaTX, Inc. · Tests: mRNA-4106, Pembrolizumab, mRNA-4200 Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis NCT05059678NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Best Practice, Educational Intervention, Questionnaire Administration A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035Phase 1, Phase 22 sites📍 Adelaide📍 Melbourne Spago Nanomedical AB · Tests: [177Lu]Lu-SN201
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy